Loteprednol Etabonate
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Loteprednol Etabonate: Serous conjunctivitis except viral
One-Sentence Summary
Loteprednol etabonate is a topical ophthalmic corticosteroid, originally used for uveitis, iritis and allergic conjunctival conditions such as atopic, vernal and papillary conjunctivitis. The TxGNN model predicts it may be effective for serous conjunctivitis except viral, but at present there are 0 clinical trials and 0 publications directly supporting this prediction, so it rests on model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Serous conjunctivitis except viral |
| TxGNN Prediction Score | 0.9969 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Other top-ranked predictions (all with the same score or slightly lower) are listed below for context:
| Rank | Predicted Indication | Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 2 | Conjunctival folliculosis | 0.9969 | L5 | Hold |
| 3 | Chronic follicular conjunctivitis | 0.9969 | L5 | Hold |
| 4 | Parasitic conjunctivitis | 0.9969 | L5 | Hold |
| 5 | Pseudomembranous conjunctivitis | 0.9966 | L5 | Hold |
| 6 | Angelucci syndrome | 0.9966 | L5 | Hold |
| 7 | Acute hemorrhagic conjunctivitis | 0.9962 | L5 | Hold |
| 9 | Acute contagious conjunctivitis | 0.9926 | L5 | Hold |
| 10 | Otitis externa | 0.9913 | L5 | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, loteprednol etabonate is a topical corticosteroid, its use in inflammatory and allergic eye conditions is established, and mechanistically it may be applicable to non-viral serous conjunctivitis.
The predicted indication is closely related to the approved ones. Non-viral serous conjunctivitis has an inflammatory component, as do atopic, vernal and papillary conjunctivitis. Anti-inflammatory steroid action is therefore plausible. However, this is a model prediction only, and no trials or literature were found to confirm it.
Among the other predictions, rosacea conjunctivitis is the most coherent. Rosacea is already among the original indications, and ocular rosacea involves eyelid and conjunctival inflammation, so this is partly an extension of an existing use. By contrast, several predictions involve infectious causes (parasitic, acute contagious, acute hemorrhagic conjunctivitis), where steroids may impair pathogen clearance and raise safety concerns.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the lead prediction (serous conjunctivitis except viral), currently no related literature available.
One paper was found for a lower-ranked prediction, pseudomembranous conjunctivitis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40638366 | 2025 | Cohort/comparative study (inferred from title) | Ocular Immunology and Inflammation | PCR-based comparison of ganciclovir and povidone-iodine, and their combination with loteprednol etabonate, for viral load reduction and clinical outcomes in adenoviral conjunctivitis. Indirect evidence only. |
India Market Information
There are 20 valid single-ingredient registrations, with no combination products and none cancelled. The records contain no approved indication text. The main authorizations are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 138185 | Moxicon LP Eye Drop | 5 ml ophthalmic suspension | Not recorded |
| 138580 | Mflotas-LP Eye Drop BKC Free | 5 ml ophthalmic suspension | Not recorded |
| 123327 | Lotefix Eye Drop | 5 ml eye drop | Not recorded |
| 121466 | Lotel Eye Ointment | 5 g eye ointment | Not recorded |
| 121080 | Lotepred T Eye Drop | 5 ml ophthalmic solution | Not recorded |
Safety Considerations
- Contraindications (from knowledge graph, not label text): ocular hypertension, glaucoma, herpes simplex virus keratitis, fungal eye infection, viral eye infection, ocular tuberculosis, ophthalmic herpes zoster.
- Drug Interactions: 30 potential interactions were identified in the interaction database, but none has a severity rating. Examples include other corticosteroids (triamcinolone, prednisone), warfarin, clopidogrel, aspirin, ibuprofen and several statins and proton pump inhibitors. Their clinical significance for a topical eye product is unclear.
- Long-term use: for chronic conditions such as chronic follicular conjunctivitis, steroid risks such as raised intraocular pressure and cataract need consideration.
- Infectious predictions: for parasitic, acute contagious, acute hemorrhagic and adenoviral conjunctivitis, local immunosuppression may worsen infection or prolong viral shedding. The knowledge graph’s viral and fungal eye infection contraindications support this concern.
Package insert warnings were not available; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (0.9969), and the drug is already widely marketed in India for related inflammatory eye conditions. However, there are no trials or literature for the lead prediction, so evidence is at L5. Several of the predicted conditions are infectious, where steroids carry real safety concerns.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator, which are currently blocking the safety screening
- Mechanism of action data (for example from DrugBank)
- A targeted literature and trial search for non-viral serous conjunctivitis and ocular rosacea
- Clarification of the approved indication wording on the Indian licenses
- A plan to exclude infectious causes and to monitor intraocular pressure if any study is designed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.